Variants in inflammatory, sex hormone metabolism, and growth factor genes and the association with benign prostatic hyperplasia

Principal Investigator

Name
Sarah Daughterty

Institution
NCI, DCEG, OEEB

About this CDAS Project

Study
PLCO (Learn more about this study)

Project ID
2007-0011

Initial CDAS Request Approval
Feb 26, 2007

Title
Variants in inflammatory, sex hormone metabolism, and growth factor genes and the association with benign prostatic hyperplasia

Summary
Benign prostatic hyperplasia (BPH), caused by an imbalance between cellular proliferation and death, is a very common problem among aging men (1). BPH is considered a syndrome by many clinicians with a constellation of symptoms that often include lower urinary tract symptoms, benign prostatic enlargement, and bladder outlet obstruction (2). Inflammatory causes, sex hormones, and growth factors may contribute to the growth or proliferation of the prostate. Due to the limited and somewhat conflicting associations reported on polymorphisms in cytokine, sex hormone metabolizing, and growth factor genes in relation to BPH, we propose to investigate susceptibility of BPH using existing genotype resources and questionnaire data already obtained within the screening arm of the PLCO Trial.

Aims

1) To assess the association between polymorphisms in inflammatory genes and risk of physician-diagnosed benign prostate hyperplasia or transurethral resection of the prostate (TURP).
2) To assess the association between polymorphisms in sex hormone metabolizing and growth factor genes and risk of physician-diagnosed benign prostate hyperplasia or TURP.

Collaborators

Elizabeth Platz (Johns Hopkins Bloomberg School of Public Health)
Richard Hayes (DCEG)
Wen-Yi Huang (DCEG)